A Phase I/II Study of VEGF-Antisense Oligonucleotide (VEGF-AS, Veglin) in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma.
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 17 Jun 2009
At a glance
- Drugs Veglin (Primary) ; Cisplatin; Pemetrexed
- Indications Mesothelioma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 08 Jan 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 20 May 2008 New trial record.